In the training cohort (from TARGET-AML), stratified analysis based on clinical characteristics revealed significant differences in DFS status between the two risk groups in several subgroups, including those with high age, female gender, CEBPA wild-type, elevated WBC count, FAB classification M4 stage, FLT3-ITD wild-type (No), and WT1 wild-type (No) (p < 0.05). The gene discussed is WT1; the disease is acute myeloid leukemia.